KR20240155987A - Uti 융합 단백질 - Google Patents

Uti 융합 단백질 Download PDF

Info

Publication number
KR20240155987A
KR20240155987A KR1020247035230A KR20247035230A KR20240155987A KR 20240155987 A KR20240155987 A KR 20240155987A KR 1020247035230 A KR1020247035230 A KR 1020247035230A KR 20247035230 A KR20247035230 A KR 20247035230A KR 20240155987 A KR20240155987 A KR 20240155987A
Authority
KR
South Korea
Prior art keywords
gly
ser
val
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247035230A
Other languages
English (en)
Korean (ko)
Inventor
애런 챔벌린
퀴앙 리우
마티아스 슈미트
Original Assignee
다케다 게엠베하
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 게엠베하, 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 게엠베하
Publication of KR20240155987A publication Critical patent/KR20240155987A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
KR1020247035230A 2014-02-24 2015-02-23 Uti 융합 단백질 Pending KR20240155987A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
US61/943,617 2014-02-24
KR1020227037377A KR102722304B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
PCT/US2015/017152 WO2015127391A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037377A Division KR102722304B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Publications (1)

Publication Number Publication Date
KR20240155987A true KR20240155987A (ko) 2024-10-29

Family

ID=52629709

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247035230A Pending KR20240155987A (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
KR1020227037377A Active KR102722304B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
KR1020167026429A Active KR102461210B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227037377A Active KR102722304B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
KR1020167026429A Active KR102461210B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Country Status (38)

Country Link
US (4) US9856310B2 (https=)
EP (2) EP3443978A1 (https=)
JP (4) JP6574431B2 (https=)
KR (3) KR20240155987A (https=)
CN (2) CN106232135B (https=)
AR (1) AR101597A1 (https=)
AU (4) AU2015218704B2 (https=)
BR (1) BR112016019390B1 (https=)
CA (2) CA2939639C (https=)
CL (1) CL2016002136A1 (https=)
CR (1) CR20160444A (https=)
CY (1) CY1120997T1 (https=)
DK (1) DK3110434T3 (https=)
DO (1) DOP2016000202A (https=)
EA (2) EA037256B1 (https=)
EC (1) ECSP16076535A (https=)
ES (1) ES2700149T3 (https=)
GE (2) GEAP201814277A (https=)
HR (1) HRP20182029T1 (https=)
IL (1) IL247321B (https=)
JO (1) JO3729B1 (https=)
LT (1) LT3110434T (https=)
MA (1) MA39347B2 (https=)
MX (4) MX384070B (https=)
MY (1) MY178774A (https=)
NZ (3) NZ760789A (https=)
PE (1) PE20170257A1 (https=)
PH (1) PH12016501629B1 (https=)
PL (1) PL3110434T3 (https=)
PT (1) PT3110434T (https=)
RS (1) RS58285B1 (https=)
SG (2) SG11201606691QA (https=)
SI (1) SI3110434T1 (https=)
SM (1) SMT201800674T1 (https=)
TW (1) TWI694084B (https=)
UA (1) UA118866C2 (https=)
WO (1) WO2015127391A1 (https=)
ZA (1) ZA201606327B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3110434T3 (pl) * 2014-02-24 2019-01-31 Takeda Gmbh Białka fuzyjne uti
WO2018226887A1 (en) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
WO2020106881A1 (en) * 2018-11-20 2020-05-28 Diamedica Inc. Modified ulinastatin polypeptides
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
US11725043B2 (en) 2020-03-05 2023-08-15 DiaMedica USA Inc. Ulinastatin polypeptides
WO2022165031A1 (en) * 2021-01-29 2022-08-04 DiaMedica USA Inc. Ulinastatin polypeptides for treating diseases
CN116903721A (zh) * 2023-06-16 2023-10-20 成都佩德生物医药有限公司 多肽pdbpe-001、其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DK0401508T3 (da) * 1989-05-13 1995-05-15 Bayer Ag Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
CA2055425A1 (en) 1990-11-13 1992-05-14 Hideaki Morishita Polypeptide, dna fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
JP3469584B2 (ja) 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
PT1730191E (pt) * 2004-03-30 2011-10-04 Glaxo Group Ltd Imunoglobulina que se liga a hosm
AU2005334481A1 (en) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
CA2609262A1 (en) * 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
PL1981519T3 (pl) 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
CA2737241C (en) * 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
WO2010129600A2 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
HUE030100T2 (en) * 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
ES2666303T3 (es) * 2011-04-29 2018-05-03 University Of Washington Composiciones terapéuticas de nucleasa y métodos
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
CA2871468C (en) * 2012-04-23 2021-09-21 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
CN103044554B (zh) * 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
PL3110434T3 (pl) * 2014-02-24 2019-01-31 Takeda Gmbh Białka fuzyjne uti

Also Published As

Publication number Publication date
MX2019013124A (es) 2020-08-31
AU2021225156A1 (en) 2021-09-30
AU2019204448B2 (en) 2021-06-10
EP3110434A1 (en) 2017-01-04
US9856310B2 (en) 2018-01-02
BR112016019390A2 (pt) 2017-10-24
PH12016501629A1 (en) 2017-02-06
EP3110434B1 (en) 2018-09-19
JP2019187427A (ja) 2019-10-31
AU2015218704A1 (en) 2016-09-22
AU2015218704B2 (en) 2019-05-02
LT3110434T (lt) 2018-12-27
DK3110434T3 (en) 2019-01-14
PT3110434T (pt) 2018-12-19
US20160362475A1 (en) 2016-12-15
KR20220151005A (ko) 2022-11-11
IL247321B (en) 2020-06-30
SG11201606691QA (en) 2016-09-29
CR20160444A (es) 2017-04-21
KR20160141718A (ko) 2016-12-09
EP3443978A1 (en) 2019-02-20
CA2939639C (en) 2023-01-24
CN110092837A (zh) 2019-08-06
PE20170257A1 (es) 2017-03-30
MX2016010950A (es) 2017-04-25
AU2021225156B2 (en) 2022-11-24
JP6938565B2 (ja) 2021-09-22
CN106232135A (zh) 2016-12-14
SG10201708400QA (en) 2017-11-29
NZ724196A (en) 2022-01-28
NZ760789A (en) 2023-03-31
CL2016002136A1 (es) 2017-08-11
EA201691702A1 (ru) 2017-01-30
JP6574431B2 (ja) 2019-09-11
KR102461210B1 (ko) 2022-10-31
SI3110434T1 (sl) 2019-02-28
PL3110434T3 (pl) 2019-01-31
MX2024000004A (es) 2024-02-20
US20220127334A1 (en) 2022-04-28
ECSP16076535A (es) 2017-08-31
TW201630931A (zh) 2016-09-01
CY1120997T1 (el) 2019-12-11
US20180072795A1 (en) 2018-03-15
US10351618B2 (en) 2019-07-16
KR102722304B1 (ko) 2024-10-28
HRP20182029T1 (hr) 2019-02-08
MA39347B2 (fr) 2020-05-29
DOP2016000202A (es) 2016-12-15
AU2019204448A1 (en) 2019-07-11
JP2023123763A (ja) 2023-09-05
US20200040062A1 (en) 2020-02-06
TWI694084B (zh) 2020-05-21
CA2939639A1 (en) 2015-08-27
IL247321A0 (en) 2016-09-29
ES2700149T3 (es) 2019-02-14
GEP20196970B (en) 2019-04-25
JP2017512058A (ja) 2017-05-18
EA202091567A1 (ru) 2021-07-30
PH12016501629B1 (en) 2023-10-20
JP2022002513A (ja) 2022-01-11
EA037256B1 (ru) 2021-02-26
NZ760008A (en) 2023-03-31
GEAP201814277A (en) 2018-12-25
UA118866C2 (uk) 2019-03-25
CA3178241A1 (en) 2015-08-27
SMT201800674T1 (it) 2019-01-11
CN106232135B (zh) 2019-12-10
MX384070B (es) 2025-03-14
AU2023200875A1 (en) 2023-04-27
RS58285B1 (sr) 2019-03-29
ZA201606327B (en) 2019-01-30
JO3729B1 (ar) 2021-01-31
MA39347A1 (fr) 2018-06-29
CN110092837B (zh) 2024-01-02
MY178774A (en) 2020-10-20
BR112016019390B1 (pt) 2023-11-14
AR101597A1 (es) 2016-12-28
WO2015127391A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
KR102722304B1 (ko) Uti 융합 단백질
KR20150041628A (ko) 인터루킨-2 융합 단백질 및 그의 용도
CN101679497A (zh) 可溶性il-17ra/rc融合蛋白以及相关方法
KR20240051971A (ko) 액티빈 수용체 ii형 신호전달 억제제를 이용한 방법
JP2022512541A (ja) Ｐｄ－１系キメラタンパク質を含む併用療法
JP2022512539A (ja) 併用療法
JP2021506772A (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
HK40004244A (en) Uti fusion proteins
HK40108366A (zh) 使用激活素受体ii型信号传导抑制剂的方法
HK1232783B (en) Uti fusion proteins
HK1232783A1 (en) Uti fusion proteins
BR122023015739B1 (pt) Proteínas de fusão uti, seus usos, composição farmacêutica compreendendo a referida proteína e método de produção de uma proteína de fusão uti

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701